SCHEMBL5366907

SCHEMBL5366907

O=C1Nc2ccc(S(=O)(=O)Nc3ccc(C(F)(F)F)cc3)cc2C1=Cc1ccc([N+](=O)[O-])c(O)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MOGAT2 Q3SYC2 1/20 0.50
NOX4 Q9NPH5 1/20 0.49
MGAT2 Q10469 2/20 0.47
GSK3B P49841 2/20 0.43
PLK4 O00444 1/20 0.41
TLK2 Q86UE8 2/20 0.40
PRKDC P78527 1/20 0.40
LRRK2 Q5S007 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
ALOX12 P18054 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5374131 0.94 MOGAT2 (0.51) MOGAT2NOX4MGAT2GSK3BPLK4
SCHEMBL5366196 0.89 MOGAT2 (0.51) MOGAT2NOX4MGAT2GSK3BTLK2
SCHEMBL5367898 0.87 MOGAT2 (0.56) MOGAT2NOX4MGAT2GSK3BLMNA
SCHEMBL7139561 0.87 MOGAT2 (0.56) MOGAT2MGAT2TLK2PRKDCLRRK2
SCHEMBL7136316 0.86 MOGAT2 (0.50) MOGAT2MGAT2GSK3BTLK2PRKDC
SCHEMBL5358368 0.86 MOGAT2 (0.61) MOGAT2MGAT2GSK3BTLK2LRRK2
SCHEMBL5361301 0.86 MOGAT2 (0.56) MOGAT2MGAT2GSK3BPLK4LRRK2
SCHEMBL5362802 0.85 MOGAT2 (0.49) MOGAT2NOX4MGAT2GSK3BPRKDC
SCHEMBL5377169 0.85 LRRK2 (0.57) MOGAT2NOX4MGAT2PLK4LRRK2
SCHEMBL5366406 0.85 MOGAT2 (0.55) MOGAT2NOX4MGAT2GSK3BPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MOGAT2 1159/4885NOX4 3452/4885MGAT2 4714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.